Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 4/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31525434 | 0.76 | KDM4E (0.39) | NPC1MAPK1ALDH1A1RAB9ALRRK2 | |
| SCHEMBL31525603 | 0.75 | MAPT (0.46) | NPC1MAPK1ALDH1A1KDM4E | |
| SCHEMBL2170098 | 0.70 | TSHR (0.44) | ADORA2AGRM5NPC1MAPK1ALDH1A1 | |
| SCHEMBL8745764 | 0.69 | NQO1 (0.42) | NQO1GRM5ALDH1A1KCNH2KDM4E | |
| SCHEMBL31525814 | 0.69 | HTR1A (0.40) | NLRP3NPC1MAPK1ALDH1A1KCNH2 | |
| SCHEMBL31589340 | 0.68 | MAPK1 (0.44) | NPC1MAPK1ALDH1A1RAB9AKDM4E | |
| SCHEMBL18151671 | 0.67 | KDM4E (0.40) | ADORA2AGRM5MAPK1ALDH1A1KDM4E | |
| SCHEMBL2952613 | 0.66 | GRM5 (0.48) | ADORA2AGRM5NLRP3NPC1MAPK1 | |
| SCHEMBL25873382 | 0.66 | NQO1 (0.40) | NQO1ALDH1A1KDM4E | |
| SCHEMBL24206916 | 0.65 | NQO1 (0.39) | NQO1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122152-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-17 | — | — | US | disclosed |
| WO-2025068943-A1 | KAT6 INHIBITORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122152-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT7 | ADORA2A 4691/4885NQO1 652/4885GRM5 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.